Neuroprotection with glatiramer acetate: Evidence from the PreCISe trial

Journal of Neurology

Volumn 260, Issue 7, 2013, Pages 1901-1906

  Arnold, Douglas L ^a   Narayanan, Sridar ^a   Antel, Samson ^a  

^a NEURORX RESEARCH   (Canada)

Author keywords

Axons; Clinical trials; Magnetic resonance imaging; Magnetic resonance spectroscopy; Multiple sclerosis; N acetylaspartate

Indexed keywords

CREATINE; GLATIRAMER; N ACETYLASPARTIC ACID; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPROTECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AXONS; BRAIN; DEMYELINATING DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PEPTIDES;

EID: 84880276763     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6903-5     Document Type: Article

References (28)

1. Dutta R, Trapp BD (2007) Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68(22 Suppl 3):S22-S31 (discussion S43-S54)
2. Redford EJ, Kapoor R, Smith KJ (1997) Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 120(Pt 12):2149-2157
3. Lassmann H (2007) Multiple sclerosis: is there neurodegeneration independent from inflammation? J Neurol Sci 259(1-2):3-6
4. Arnold DL, Matthews PM, Francis G, Antel J (1990) Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 14:154-159
5. De Stefano N, Matthews PM, Arnold DL (1995) Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 34(5):721-727
6. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, Antel JP (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 36(1):76-82
7. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121(Pt 1):103-113
8. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Targaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58(1):65-70
9. Narayanan S, Caramanos Z, Arnold DL (2004) The effect of glatiramer acetate on axonal integrity in multiple sclerosis. (Abstract). Mult Scler 10(2):S256
10. Khan O, Shen Y, Caon C, en Bao F, Ching W, Reznar M, Buccheister A, Hu J, Latif Z, Tselis A, Lisak R (2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11(6):646-651
11. Khan O, Shen Y, en Bao F, Caon C, Tselis A, Latif Z, Zak I (2008) Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term H-MRS monitoring in multiple sclerosis. J Neuroimaging 18(3):314-319
12. Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503-1511
13. Comi G, Martinelli V, Rodegher M et al (2012) Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. doi: 10.1177/1352458512469695
14. Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30(6):672-679
15. Dautry C, Vaufrey F, Brouillet E, Bizat N, Henry PG, Condé F, Bloch G, Hantraye P (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20(5):789-799
16. Miller DH, Soon D, Fernando KT et al (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68(17):1390-1401
17. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L, Multiple Sclerosis Collaborative Research Group (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53(8):1698-1704
18. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, Pelletier D, Arnason BGW, Antel JP, Arnold DL (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248(11):979-986
19. Parry AM, Scott RB, Palace J, Smith S, Matthews PM (2003) Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 126(Pt 12):2750-2760
20. Filippi M, Wolinsky JS, Comi G (2006) Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 5(3):213-220
21. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D, Promise Study Group (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61(1):14-24
22. Sajja BR, Narayana PA, Wolinsky JS, Ahn CW (2008) Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler 14(1):73-80
23. Brown RA, Cook S, Cadavid D, Wolansky L, Narayanan S, Arnold DL (2013) Effect of interferon beta-1b and glatiramer acetate on new MTR brain lesions in MS. Abstract presented at the 65th Annual meeting of the American Academy of Neurology, San Diego, PO7.104, March 16-23
24. Kirov II, Tal A, Babb JS, Herbert J, Gonen O (2013) Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology 80:39-46
25. Anderson VM, Fernando KT, Davies GR, Rashid W, Frost C, Fox NC, Miller DH (2007) Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. J Neuroimaging 17(1):61-68
26. Helms G (2001) Volume correction for edema in single-volume proton MR spectroscopy of contrast-enhancing multiple sclerosis lesions. Magn Reson Med 46(2):256-263
27. Ratiney H, Noworolski SM, Sdika M, Srinivasan R, Henry RG, Nelson SJ, Pelletier D (2007) Estimation of metabolite T1 relaxation times using tissue specific analysis, signal averaging and bootstrapping from magnetic resonance spectroscopic data. Magn Reson Mater Phy 20:143-145
28. Caramanos Z, Narayanan S, Arnold DL (2005) 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 128(Pt 11):2483-2506